Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 210 participants.
Also called NCT03574311
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 210 participants
- Sponsor
- Registry
-
NCT03574311
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Finland
- Registry status
- Unknown status
Technical summary
Registry record NCT03574311. Randomized; triple masking; primary purpose prevention. Start 2018-10-02 (actual); primary completion 2022-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery
- Acronym
- PREFER-CABG
- Condition
- Coronary Artery Disease
- Condition
- Postoperative Complications
- Condition
- Aortic Valve Stenosis
- Condition
- Mitral Valve Disease
- Condition
- Aortic Aneurysm, Thoracic
- Intervention (Drug)
- Ferric carboxymaltose
- Intervention (Other)
- Physiological saline
- Lead sponsor
- Turku University Hospital
- Collaborator
- Vifor Pharma
Record details
- Record id
cardio:ct-nct03574311- Content hash
fcda3621ae0c12c2feaf270f9faac9fd8501692f4c06a052913abc92f0454b6a